Oncolytics Biotech announced that two of its pelareorep studies were accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, scheduled for April 17‑22 in San Diego. The accepted abstracts come from the AWARE‑1 breast‑cancer study and the GOBLET gastrointestinal‑cancer trial.
The AWARE‑1 abstract reports that pelareorep treatment in early‑stage breast‑cancer patients induced coordinated immune activation and the formation of tertiary lymphoid structures (TLS). TLS are localized immune hubs that enhance antigen presentation and T‑cell activation, and their presence has been linked to improved responses to checkpoint inhibitors. This finding demonstrates pelareorep’s ability to convert immunologically cold tumors into hot, checkpoint‑responsive lesions.
The GOBLET abstract shows that in metastatic pancreatic‑cancer patients, pelareorep combined with atezolizumab, gemcitabine, and nab‑paclitaxel produced early immune‑activation signatures that correlated with longer progression‑free survival—7.5 months versus 5.6 months for non‑activated patients. The data reinforce pelareorep’s role as a systemic immune‑priming agent across distinct tumor types.
The acceptance of these abstracts signals progress toward Oncolytics’ goal of establishing pelareorep as a foundational backbone for combination oncology therapies. By showcasing mechanistic depth at a leading conference, the company positions itself to attract partnership interest and strengthen its case for future regulatory submissions.
The findings support Oncolytics’ broader strategy of combining pelareorep with standard chemotherapies and checkpoint inhibitors, potentially expanding its therapeutic reach across multiple indications.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.